Gregory Parks

Preclinical Pharmacology of Solriamfetol: Potential Mechanisms for Wake Promotion

Abstract: Introduction: Solriamfetol is a wake-promoting agent (WPA) approved for the treatment of excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea. The...

Gregory Parks ;

Craig Chepke , MD, DFAPA;

01/25/2023

Solriamfetol Improves Cognitive Performance in Preclinical Models of Sleep Apnea and in a Randomized Placebo-controlled Study of Sleep Apnea Participants (SHARP)

Solriamfetol is a dopamine-norepinephrine reuptake inhibitor (DNRI) that improves wakefulness in adults with EDS and OSA. Beyond inhibiting DAT/NET, solriamfetol demonstrated agonist acti...

Gregory Parks ;

10/26/2023

Excessive Daytime Sleepiness in a Real-World Study of Participants With OSA With or Without Comorbid Depression

Abstract: Background: Obstructive sleep apnea (OSA) is a common sleep disorder that is often associated with medical and psychiatric comorbidities. Patients with OSA experience many sympt...

Gregory Parks ;

01/19/2023

Comorbidities and Presenting Symptoms in a Real-World Population With Obstructive Sleep Apnea

Abstract: Background: Obstructive sleep apnea (OSA) is a sleep disorder that is often comorbid with psychiatric disorders. Excessive daytime sleepiness (EDS) is common in both psychiatric...

Gregory Parks ;

01/19/2023